Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...
WIAT Birmingham on MSN3h
MMRF Multiple Myeloma Community Connect event to be held Nov. 14MMRF Multiple Myeloma Community Connect event to be held Nov. 14 ...
If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
KRd56 and KRd27 regimens showed no significant difference in ORR or PFS for relapsed/refractory multiple myeloma patients. Both regimens had similar safety profiles, with common side effects like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback